CN108883202A - 用于癌症治疗的工程化的哺乳动物细胞 - Google Patents

用于癌症治疗的工程化的哺乳动物细胞 Download PDF

Info

Publication number
CN108883202A
CN108883202A CN201780010175.2A CN201780010175A CN108883202A CN 108883202 A CN108883202 A CN 108883202A CN 201780010175 A CN201780010175 A CN 201780010175A CN 108883202 A CN108883202 A CN 108883202A
Authority
CN
China
Prior art keywords
cells
pharmaceutical composition
promoter
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780010175.2A
Other languages
English (en)
Chinese (zh)
Inventor
范晓虎
章方良
庄秋传
王平艳
郁洁
何娴
王林
郝佳瑛
杨蕾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Publication of CN108883202A publication Critical patent/CN108883202A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
CN201780010175.2A 2016-02-04 2017-01-26 用于癌症治疗的工程化的哺乳动物细胞 Pending CN108883202A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016073489 2016-02-04
CNPCT/CN2016/073489 2016-02-04
PCT/CN2016/087855 WO2017133175A1 (en) 2016-02-04 2016-06-30 Engineered mammalian cells for cancer therapy
CNPCT/CN2016/087855 2016-06-30
PCT/CN2017/072723 WO2017133633A1 (en) 2016-02-04 2017-01-26 Engineered mammalian cells for cancer therapy

Publications (1)

Publication Number Publication Date
CN108883202A true CN108883202A (zh) 2018-11-23

Family

ID=59499323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780010175.2A Pending CN108883202A (zh) 2016-02-04 2017-01-26 用于癌症治疗的工程化的哺乳动物细胞

Country Status (5)

Country Link
US (1) US20190038671A1 (https=)
EP (1) EP3411079A4 (https=)
JP (1) JP2019504892A (https=)
CN (1) CN108883202A (https=)
WO (2) WO2017133175A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
CN114555809A (zh) * 2019-08-28 2022-05-27 森迪生物科学公司 组合癌症免疫疗法
CN114787373A (zh) * 2019-07-25 2022-07-22 免疫苏醒公司 测量通过效应子进行的细胞介导的杀伤的方法

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
KR20240024328A (ko) 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
AU2018223211B2 (en) * 2017-02-21 2025-02-27 Adelaide university T cells expressing chemokine receptors for treating cancer
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
AU2018254517A1 (en) * 2017-04-19 2019-12-05 University Of Southern California Compositions and methods for treating cancer
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
AU2018329741B2 (en) * 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
WO2019077037A1 (en) * 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
JP2021514187A (ja) * 2018-02-15 2021-06-10 ザ ナショナル インスティテュート フォー バイオテクノロジー イン ザ ネゲヴ リミテッドＴｈｅ Ｎａｔｉｏｎａｌ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎ Ｔｈｅ Ｎｅｇｅｖ Ｌｔｄ． キメラ抗原受容体の腫瘍環境特異的発現
CN111867598A (zh) * 2018-03-13 2020-10-30 国立大学法人大阪大学 肿瘤免疫赋活剂
EP3781176A4 (en) * 2018-04-09 2022-05-25 The Trustees of the University of Pennsylvania METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
CN108913718A (zh) * 2018-07-20 2018-11-30 苏州茂行生物科技有限公司 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
CN108949825A (zh) * 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
CN113166778A (zh) * 2018-09-05 2021-07-23 葛兰素史克知识产权开发有限公司 T细胞修饰
US12097219B2 (en) 2018-09-10 2024-09-24 Legend Biotech Ireland Limited Single-domain antibodies against CLL1 and constructs thereof
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
WO2020118094A1 (en) * 2018-12-06 2020-06-11 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
JP2022521486A (ja) * 2019-02-08 2022-04-08 ディーエヌエイ ツーポイント インコーポレイテッド トランスポゾンに基づく免疫細胞の改変
WO2020172553A1 (en) * 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020181221A1 (en) * 2019-03-07 2020-09-10 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
US20220204575A1 (en) * 2019-04-23 2022-06-30 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN114450397A (zh) * 2019-08-01 2022-05-06 纪念斯隆-凯特琳癌症中心 用于改善免疫疗法的细胞及其用途
JP7831937B2 (ja) 2019-09-03 2026-03-17 クリエイト・メディシンズ，インコーポレーテッド ゲノム組込みのための方法および組成物
MX2022004772A (es) * 2019-10-22 2022-07-19 Alloplex Biotherapeutics Composiciones y métodos para la activación y la expansión in vitro de poblaciones de linfocitos t citolíticos en serie e inmunización pasiva de un paciente de cáncer con células tumorales asesinas.
CN115297873A (zh) * 2019-11-08 2022-11-04 梅约医学教育与研究基金会 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CA3164706A1 (en) * 2020-01-14 2021-07-22 Jonathan David SILK Method of treatment of cancer or tumour
IL295896A (en) 2020-02-26 2022-10-01 Biograph 55 Inc c19 c38 bispecific antibodies
CN115335087A (zh) * 2020-04-01 2022-11-11 南京传奇生物科技有限公司 用于减少同种异体细胞疗法中的移植物排斥的组合物和方法
WO2022005994A1 (en) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center C825 expressing immune cells and diagnostic uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
JP7849891B2 (ja) * 2020-08-24 2026-04-22 シャリテ－ウニベルジテーツメディツィン ベルリン Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞
WO2022093884A1 (en) * 2020-10-27 2022-05-05 Pact Pharma, Inc. Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
JP2024524983A (ja) * 2021-06-24 2024-07-09 ジョージア テック リサーチ コーポレイション 熱標的化によるｔ細胞療法の遠隔制御のための方法及び組成物
CN113789299B (zh) * 2021-10-18 2023-03-24 新鲁细胞生物科技(海南)有限公司 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法
EP4598553A1 (en) * 2022-10-07 2025-08-13 Senti Biosciences, Inc. Armed chimeric receptors and methods of use thereof
WO2024107410A1 (en) * 2022-11-14 2024-05-23 The Board Of Trustees Of The Leland Stanford Junior University Cd39 selection for cytotoxicity of genetically engineered t regulatory cells
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival
WO2025081190A1 (en) * 2023-10-12 2025-04-17 Georgia Tech Research Corporation Image guided car t cell therapy to treat brain tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068334A (zh) * 1991-06-03 1993-01-27 免疫生物学研究所有限公司 适用于调节免疫系统及神经系统的肽
CN1299411A (zh) * 1997-11-03 2001-06-13 亚利桑那董事会（代表亚利桑那大学） 用于基因治疗的高温诱导表达载体及其使用方法
CN1753912A (zh) * 2002-12-23 2006-03-29 惠氏公司 抗pd－1抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2366787B1 (en) * 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
EP3692794A1 (en) * 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
DK2958943T3 (da) * 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
US20170081411A1 (en) * 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
SI3151672T1 (sl) * 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
WO2016014530A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
HK1254803A1 (zh) * 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068334A (zh) * 1991-06-03 1993-01-27 免疫生物学研究所有限公司 适用于调节免疫系统及神经系统的肽
CN1299411A (zh) * 1997-11-03 2001-06-13 亚利桑那董事会（代表亚利桑那大学） 用于基因治疗的高温诱导表达载体及其使用方法
CN1753912A (zh) * 2002-12-23 2006-03-29 惠氏公司 抗pd－1抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAIYER A RIZVI ET AL.: "Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate 063):a phase 2,single-arm trial.", 《LANCET ONCOL》 *
火俊等: "免疫调节剂治疗多发性骨髓瘤的抗血管生成及免疫调节作用机制", 《第二军医大学学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787373A (zh) * 2019-07-25 2022-07-22 免疫苏醒公司 测量通过效应子进行的细胞介导的杀伤的方法
CN114555809A (zh) * 2019-08-28 2022-05-27 森迪生物科学公司 组合癌症免疫疗法
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用

Also Published As

Publication number Publication date
JP2019504892A (ja) 2019-02-21
US20190038671A1 (en) 2019-02-07
EP3411079A1 (en) 2018-12-12
WO2017133175A1 (en) 2017-08-10
WO2017133633A1 (en) 2017-08-10
EP3411079A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
WO2017133633A1 (en) Engineered mammalian cells for cancer therapy
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US20240083968A1 (en) Treatment of cancer using chimeric cd3 receptor proteins
JP7249287B2 (ja) Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
WO2020228825A1 (en) Engineered immune cells comprsing a recognition molecule
JP2023052446A (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
JP7034934B2 (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
US11723962B2 (en) Cell-based neoantigen vaccines and uses thereof
JP2024167225A (ja) キメラ抗原受容体とｐｄ－１阻害薬との併用療法
US20190375815A1 (en) Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
JP2022043043A (ja) 免疫細胞の有効性および増大を改善する方法
WO2020147708A1 (en) Chimeric receptor polypeptides and uses thereof
JP2020534871A (ja) キメラエンガルフメント受容体分子および使用方法
JP2018516592A (ja) キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
US20240366761A1 (en) Fusion proteins and uses thereof
JP2025524921A (ja) 細胞療法の持続性を促進するための方法
WO2025201418A1 (en) Engineered immune cells and uses thereof
HK40113958A (zh) 包含cd4结合部分的免疫细胞受体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123